GeneDx Investors Face August 3 Deadline in Securities Fraud Lawsuit

The legal action, filed by Hagens Berman Sobol Shapiro LLP, centers on the period between April 16, 2025, and May 4, 2026. Plaintiffs claim GeneDx executives misled shareholders by promoting the Fabric Genomics acquisition as an AI-driven catalyst for growth and efficiency, while allegedly concealing internal integration failures and operational disconnects.

The facade of synergy collapsed on May 4, 2026, when GeneDx disclosed a series of disappointing financial results. The company reported missed revenue targets for its exome and genome testing lines and a decline in adjusted gross margins from 74% to 69%. Perhaps most damaging was a $31.2 million impairment charge related to Fabric Genomics—effectively erasing 94% of the cash spent on the acquisition just one year prior. Following these disclosures, the company slashed its full-year 2026 revenue guidance to a range of $475 million–$490 million, down from earlier projections of $550 million.

Market reaction was swift and severe. WGS shares fell 49.2% in a single trading session, dropping from $67.93 to $34.51 and wiping out billions in shareholder value. Reed Kathrein, the Hagens Berman partner leading the investigation, stated that the firm is scrutinizing management’s public statements regarding the acquisition's supposed technological benefits. Investors who incurred losses during the class period are encouraged to contact the firm before the August 3 deadline to participate in the court-appointed lead plaintiff process.